Compare
Galmed Pharmaceuticals Ltd. vs Lite Strategy, Inc. vs Genelux Corp vs Marker Therapeutics, Inc.
| Latest fiscal year | Galmed Pharmaceuticals Ltd. EOCN | Lite Strategy, Inc. LITS | Genelux Corp GNLX | Marker Therapeutics, Inc. MRKR |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $0 | $8.0K | $3.55M |
| Revenue growth (YoY) | n/a | -100.0% | 0.0% | -46.2% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | n/a | n/m | -363.5% |
| Net margin | n/a | n/a | n/m | -343.0% |
| Net income | $6.90M | -$15.95M | -$32.15M | -$12.16M |
| EPS (Diluted) | $2.39 | -$2.39 | -$0.86 | -$0.79 |
| Operating cash flow | -$6.32M | -$20.84M | -$25.27M | -$12.01M |
| Free cash flow | n/a | -$20.84M | -$26.37M | n/a |
| Cash & equivalents | $3.98M | $18.01M | $5.33M | $16.07M |
| Total assets | $18.63M | $18.29M | $19.03M | $19.07M |
| Total liabilities | n/a | $1.35M | $7.48M | $2.27M |
| Shareholders' equity | $15.78M | $16.93M | $11.54M | $16.80M |
| Return on year-end equity | 43.7% | -94.2% | -278.5% | -72.4% |
| Shares outstanding | 6.58M | 6.66M | 38.14M | 16.70M |
Revenue, most recent five fiscal years
| Fiscal year | Galmed Pharmaceuticals Ltd. | Lite Strategy, Inc. | Genelux Corp | Marker Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | $0 Ended 2020-12-31 | $0 Ended 2025-06-30 | $8.0K Ended 2025-12-31 | $3.55M Ended 2025-12-31 |
| 1 year earlier | $0 Ended 2019-12-31 | $65.30M Ended 2024-06-30 | $8.0K Ended 2024-12-31 | $6.59M Ended 2024-12-31 |
| 2 years earlier | $2.04M Ended 2018-12-31 | $48.82M Ended 2023-06-30 | $170.0K Ended 2023-12-31 | $3.31M Ended 2023-12-31 |
| 3 years earlier | $1.08M Ended 2017-12-31 | $40.70M Ended 2022-06-30 | $11.07M Ended 2022-12-31 | $3.51M Ended 2022-12-31 |
| 4 years earlier | $467.0K Ended 2016-12-31 | $34.80M Ended 2021-06-30 | n/a | $1.24M Ended 2021-12-31 |